Focus Area Personalized Oncology
Vision
Our vision is to advance personalized medicine in oncology by optimizing processes in molecular tumor boards and integrating comprehensive patient-reported outcome measures (PROMs). We aim to improve cancer treatment that is highly individualized based on advanced bioinformatic analyses of RNA sequencing and single-cell RNA sequencing. By improving decision-making processes and incorporating patient perspectives, we aim to sustainably improve treatment outcomes and the quality of life of cancer patients.
Our main task is to optimize the functionality and effectiveness of molecular tumor boards by integrating advanced bioinformatic approaches. With a focus on the analysis of RNA and single-cell RNA sequencing data, we aim to develop precise and personalized therapy recommendations. In addition, we are committed to integrating patient-reported outcome measures into oncology workflows to ensure that treatment strategies are not only effective, but also in line with patients' quality of life and personal goals.
Focus Areas
- Optimizing the functionality and effectiveness of molecular tumor boards through the integration of new bioinformatics approaches
- Focus on the analysis of RNA- and single-cell-RNA-sequencing data
- Integration of patient-reported outcome measures, so-called "PROs", into oncology workflows
- Evaluation of harmonized data in OMOP using AI algorithms
Contact Person
© MF/Stephan Wiegand
Research fellow
NameMr Dr.-Ing. Markus Wolfien
Send encrypted email via the SecureMail portal (for TUD external users only).
Selected Projects
- MiHUBx — Use Case 3 Onkologie - Verbesserung des Patientenpfades für das Molekulare Tumor Board
- MutRad - Verbesserung des Strahlenschutzes mit Hilfe von Genexpressionsdaten
- PM4Onco — Personalized Medicine for Oncology